ANIKAnika Therapeutics, Inc.

$213M

Q4 2020 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$33M+9.8% YoY

Gross Profit

$17M51.2% margin

Operating Income

-$18M-54.9% margin

Net Income

-$16M-47.9% margin

EPS (Diluted)

$-1.10

QoQ Revenue Growth

+3.1%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

$2M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$366M

Total Liabilities

$93M

Stockholders' Equity

$272M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$30M	+9.8%
Gross Profit	$17M	$21M	-20.7%
Operating Income	-$18M	$5M	-473.9%
Net Income	-$16M	$4M	-486.5%

Revenue Segments

Product

$33M63%

Joint Pain Management Therapies

$17M32%

Manufactured Product, Other

$3M5%

Geographic Segments

UNITED STATES

$25M89%

Europe

$3M11%

ANIK Q4 2020 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena